Osiris Therapeutics
Shares rose 79 cents, or 6.4 percent, to $13.12. The Columbia-based developer of treatments using adult stem cells said its experimental therapy Prochymal was given fast-track review by the FDA.
Stock of interest
The Baltimore Sun
Copyright
© 2021, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad